Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Treatment-Resistant Depression (G2K)
NCT06668571Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in treatment-resistant depression (TRD), sponsored by Mayo Clinic. Started Feb 2025; status: recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06668571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668571.